

<b>Study Title:</b>	A Phase 2 Trial of Cvac (Autologous Dendritic Cells Pulsed with Recombinant Human Fusion Protein [Mucin 1-Glutathione S-Transferase] Coupled to Oxidized Polymannose) in Patients with Resected Stage I or Stage II Adenocarcinoma (Cancer) of the Pancreas
<b>Test Drug:</b>	Cvac (autologous dendritic cells treated with mannosylated mucin 1 fusion protein)
<b>Indication:</b>	Pancreatic cancer
<b>Sponsor:</b>	Prima BioMed Ltd.
<b>Study No.:</b>	CAN-301
<b>EudraCT No.:</b>	2014-000676-26
<b>Study Phase:</b>	2
<b>Study Initiation date: (first patient screened)</b>	Study was terminated prior to study start
<b>Study Completion Date:</b>	Study terminated 13 March 2015
<b>Reason for Termination of Study:</b>	<b>Due to company restructuring and prioritization</b>